Posted by Michael Wonder on 02 Aug 2022
SK bioscience submits application for conditional marketing authorisation of COVID-19 vaccine, SKYCovion to European Medicines Agency
1 August 2022 - SK bioscience will accelerate to apply for emergency use listing to the World Health Organization.
SK bioscience today announced that the company has submitted an application for a conditional marketing authorisation of the COVID-19 vaccine, SKYCovion to the EMA, following U.K. submission.
